The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: 90-Day Results.
Study Design
- Tipo de Estudo
- randomized controlled trial
- Tamanho da Amostra
- 60
- Duração
- 12.9 weeks
- Intervenção
- The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto (Serenoa repens) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self-Perceived Thinning Hair: Proprietary saw palmetto (Serenoa repens) bioactive fatty acids extract, 1 oral dose daily for 90 da
- Comparador
- Placebo
- Direção do Efeito
- Positive
- Risco de Viés
- Low
Abstract
BACKGROUND: Hair loss is a global concern for both men and women. AIMS: This study assessed the efficacy and safety of a proprietary extract of bioactive fatty acids from saw palmetto for treating self-perceived thinning hair in healthy adult male and female subjects. METHODS: In this 6-month, randomized, double-blind, placebo-controlled study, subjects were randomized to receive active treatment (n = 40) or placebo (n = 20). Half of the enrolled subjects were female. Subjects took one oral dose of their assigned treatment daily. Assessments were performed at baseline, Day 56 and Day 90. Preliminary 90-day results are presented here. PATIENTS/METHODS: The active group showed significant improvement in terminal hair count from baseline in anterior (p < 0.0007) and posterior (p < 0.0005) areas. Compared to placebo, the improvement was also significant in the anterior (p < 0.05) and posterior (p < 0.03) areas. Anterior vellus hair count improved significantly versus baseline (p < 0.0005) and placebo (p < 0.01). Posterior vellus hair count showed significant within-group growth (p < 0.05). Total hair count was significantly greater than baseline for anterior (p < 0.001) and posterior (p < 0.0005) and significantly greater for anterior (p < 0.005) and posterior (p < 0.05) compared to placebo. Total terminal hair counts improved 7-fold, and total hair count improved 12-fold compared to placebo. A significant reduction in hair shedding was observed in the active group versus baseline (p < 0.05). No meaningful improvements were observed in the placebo group, and no adverse events were reported. CONCLUSION: These preliminary results indicate the daily administration of a proprietary saw palmetto (Serenoa repens) extract safely and effectively promotes hair growth in men and women with self-perceived thinning hair. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT06920758.
Full Text
Figures
FIGURE 1
Study design or participant flow for the clinical trial assessing a proprietary saw palmetto bioactive fatty acids extract for promoting hair growth in adults with self-perceived thinning hair.
flowchart
FIGURE 2
Hair growth outcome measures showing improvements in hair density or shedding rates in participants receiving the saw palmetto extract compared with baseline or control.
chartTables
TABLE 1
| Active | Placebo | |
|---|---|---|
|
|
| |
| Mean age, years (SD) | 50.6 (9.6) | 48.9 (10.9) |
| Median age, years (min, max) | 55.0 (28, 63) | 50.5 (29, 63) |
| Race, |
|
|
| White | 36 (90) | 14 (70) |
| Black | 1 (2.5) | 1 (5) |
| Asian | 1 (2.5) | 2 (10) |
| American Indian/Alaskan Native | — | 2 (10) |
| Native Hawaiian/Pacific Islander | — | 1 (5) |
| Mixed race | 2 (5) | — |
| Ethnicity, |
|
|
| Hispanic/Latino | 32 (80) | 15 (75) |
| Non‐Hispanic/Latins | 8 (20) | 5 (25) |
| Fitzpatrick skin type |
|
|
| Type I | 6 (15) | 5 (25) |
| Type II | 14 (35) | 4 (20) |
| Type III | 12 (30) | 5 (25) |
| Type IV | 6 (15) | 5 (25) |
| Type V | 2 (5) | — |
| Type VI | — | 1 (5) |
| Norwood classification scale (male subjects), |
|
|
| II | 1 (5) | 1 (10) |
| III | 8 (40) | 7 (70) |
| III Vertex | 11 (55) | 2 (20) |
| Savin pictorial scale (female subjects), |
|
|
| 1–2 | 15 (75) | 7 (70) |
| 1–3 | 5 (25) | 3 (30) |
TABLE 2
| Active ( | Placebo ( | |||||
|---|---|---|---|---|---|---|
| Day 0 | Day 90 | Change | Day 0 | Day 90 | Change | |
|
| ||||||
| Mean (SD) | 132.9 (29.2) | 144.2 (32.4) | +11.3 (19.4)a,b | 131.8 (30.7) | 134.4 (28.9) | +2.7 (14.2) |
| Median (min, max) | 134.5 (60, 202) | 145.0 (70, 206) | 10.5 (70, 206) | 137.5 (85, 199) | 135.5 (85, 210) | 2.0 (−28, 34) |
|
a
b
| ||||||
|
| ||||||
| Mean (SD) | 167.1 (32.9) | 179.2 (34.0) | +12.1 (18.7)a,b | 175.2 (34.6) | 175.6 (31.7) | +0.6 (18.6) |
| Median (min, max) | 168 (100, 233) | 183 (105, 258) | 12 (−20, 41) | 175 (123, 246) | 172 (117, 232) | 3 (−39, 31) |
|
a
b
| ||||||
|
| ||||||
| Mean (SD) | 10.8 (9.5) | 15.2 (12.6) | +4.4 (9.2)a,b | 14.9 (10.9) | 12.2 (11.4) | −2.7 (10.7) |
| Median (min, max) | 8 (0, 37) | 11 (0, 50) | 3.5 (−11, 28) | 14 (0, 35) | 8.5 (0, 41) | −1.5 (−32, 11) |
|
a
b
| ||||||
|
| ||||||
| Mean (SD) | 4.8 (6.6) | 5.8 (6.9) | +1.0 (8.0) | 3.5 (3.1) | 5.4 (4.7) | +1.9 (4.2) |
| Median (min, max) | 1 (0, 29) | 3 (0, 31) | 0 (−22, 20) | 3 (0, 11) | 4.5 (0, 14) | 0 (−6, 10) |
|
| ||||||
| Mean (SD) | 143.7 (28.0) | 159.4 (30.7) | +15.7 (18.5)a,b | 146.7 (33.3) | 146.6 (27.4) | −0.1 (19.8) |
| Median (min, max) | 146.5 (66, 206) | 155.5 (97, 219) | 13.5 (−31, 52) | 142 (98, 222) | 139.5 (101, 213) | −1 (−36, 39) |
|
a
b
| ||||||
|
| ||||||
| Mean (SD) | 171.9 (35.4) | 185.0 (36.0) | +13.10 (21.4)a,b | 178.7 (33.3) | 181.0 (30.2) | +2.3 (18.5) |
| Median (min, max) | 171 (100, 246) | 190 (105, 272) | 11 (−42, 58) | 178 (130, 249) | 174.5 (127, 232) | 3 (−31, 39) |
|
a
b
| ||||||
TABLE 3
| Day 0 | Day 90 | Change | Day 0 | Day 90 | Change | |
|---|---|---|---|---|---|---|
|
|
| |||||
| Mean (SD) | 128.6 (23.76) | 138.6 (29.45) | +10 (15.27)a | 185.87 (23.98) | 191.8 (27.49) | +5.93 (19.45) |
| Median (min, max) | 128 (82, 169) | 142 (90, 206) | 8 (−15, 37) | 194 (142, 220) | 193 (146, 258) | 6 (−20, 39) |
|
a
| ||||||
|
|
| |||||
| Mean (SD) | 13.6 (9.88) | 19.47 (15.59) | +5.87 (11.46) | 5.47 (8.88) | 6.00 (5.98) | +0.53 (9.28) |
| Median (min, max) | 12 (0, 37) | 20 (0, 50) | 6 (−11, 28) | 0 (0, 29) | 6 (0, 15) | 0 (−22, 15) |
|
|
| |||||
| Mean (SD) | 142.2 (23.15) | 158.07 (28.15) | +15.87 (16.77)a | 191.33 (28.95) | 197.8 (29.5) | +6.47 (22.47) |
| Median (min, max) | 145 (96, 178) | 155 (110, 206) | 13 (−11, 52) | 194 (142, 238) | 196 (146, 272) | 10 (−42, 39) |
|
a
| ||||||
TABLE 4
| Active ( | Placebo ( | |||||
|---|---|---|---|---|---|---|
| Day 0 | Day 90 | Change | Day 0 | Day 90 | Change | |
|
| ||||||
| Mean (SD) | 1.2 (1.0) | 0.8 (0.9) | −0.4 (1.1)a | 1.1 (1.3) 1.0 (0.9) | 1.0 (0.9) | −0.2 (1.3) |
| Median (min, max) | 1 (0, 3) | 1 (0, 3) | 0 (−3, 2) | 1 (0, 4) | 1 (0, 4) | 0 (−3, 4) |
|
a
| ||||||
|
| ||||||
| Mean (SD) | 0.5 (0.6) | 0.3 (0.6) | −0.2 (0.7) | 0.8 (0.8) | 0.4 (0.6) | −0.4 (0.9) |
| Median (min, max) | 0 (0, 2) | 0 (0, 2) | 0 (−2, 1) | 1 (0, 3) | 0 (0, 2) | 0 (−2, 2) |
|
| ||||||
| Mean (SD) | 0.2 (0.5) | 0.1 (0.2) | −0.1 (0.5) | 0.1 (0.3) | 0.1 (0.2) | −0.1 (0.2) |
| Median (min, max) | 0 (0, 2) | 0 (0, 1) | 0 (−1, 1) | 0 (0, 1) | 0 (0, 1) | 0 (−1, 0) |
|
| ||||||
| Mean (SD) | 0.2 (0.4) | 0.1 (0.3) | −0.1 (0.6) | 0.2 (0.4) | 0.3 (0.4) | 0.1 (0.6) |
| Median (min, max) | 0 (0, 1) | 0 (0, 1) | 0 (−1, 1) | 0 (0, 1) | 0 (0, 1) | 0 (−1, 0) |
|
| ||||||
| Mean (SD) | 0.4 (0.7) | 0.3 (0.5) | −0.1 (0.7) | 0.3 (0.7) | 0.3 (0.4) | −0.1 (0.9) |
| Median (min, max) | 0 (0, 3) | 0 (0, 2) | 0 (−2, 1) | 0 (0, 3) | 0 (0, 1) | 0 (−3, 1) |
TABLE 5
| Rating | Active ( | Placebo ( |
|---|---|---|
|
| ||
| Greatly improved | 1 (2.5) | — |
| Moderately improved | 10 (25) | 4 (20) |
| Slightly improved | 21 (52.5) | 6 (30) |
| No change | 3 (7.5) | 7 (35) |
| Slightly worsened | 5 (12.5) | 3 (15) |
| Moderately worsened | — | — |
| Greatly worsened | — | — |
|
| ||
| Greatly increased | — | — |
| Moderately increased | 9 (23) | 2 (10) |
| Slightly increased | 15 (38) | 4 (20) |
| No change | 9 (23) | 9 (45) |
| Slightly decreased | 7 (18) | 5 (25) |
| Moderately decreased | — | — |
| Greatly decreased | — | — |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
Expert opinion on pharmacotherapy · 2020
A review of the treatment of male pattern hair loss.
Journal of cosmetic dermatology · 2019
An overview of herbal alternatives in androgenetic alopecia.
International journal of immunopathology and pharmacology · 2012
Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study.
Archives of dermatological research · 2020
Herbal preparations for the treatment of hair loss.
Dermatologic therapy · 2022
Natural products for male androgenetic alopecia.
Evidence-based complementary and alternative medicine : eCAM · 2011